BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12866577)

  • 41. Comparison of multiplex ligation dependent probe amplification to immunohistochemistry for assessing HER-2/neu amplification in invasive breast cancer.
    Purnomosari D; Aryandono T; Setiaji K; Nugraha SB; Pals G; van Diest PJ
    Biotech Histochem; 2006; 81(2-3):79-85. PubMed ID: 16908432
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dual fluorescence in situ hybridization in detection of HER-2 oncogene amplification in primary hepatocellular carcinoma.
    Huang TJ; Huang BJ; Liang QW; Huang CW; Fang Y
    Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):62-8. PubMed ID: 14969840
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Quantitative detection of HER-2 oncogene amplification in primary hepatocellular carcinoma using dual FISH technique and its clinical significance].
    Huang BJ; Huang TJ; Liang QW; Huang CW; Fang Y
    Yi Chuan Xue Bao; 2001; 28(9):793-800. PubMed ID: 11582736
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lower HER-2/chromosome enumeration probe 17 ratio in cytologic HER-2 fluorescence in situ hybridization for breast cancers: three-dimensional analysis of intranuclear localization of centromere 17 and HER-2 signals.
    Itoh H; Miyajima Y; Umemura S; Osamura RY
    Cancer; 2008 Apr; 114(2):134-40. PubMed ID: 18306351
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
    Tsiambas E; Karameris A; Dervenis C; Lazaris AC; Giannakou N; Gerontopoulos K; Patsouris E
    JOP; 2006 May; 7(3):283-94. PubMed ID: 16685109
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?
    Bhargava R; Lal P; Chen B
    Am J Clin Pathol; 2005 Feb; 123(2):237-43. PubMed ID: 15842048
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.
    Vanden Bempt I; Vanhentenrijk V; Drijkoningen M; Wlodarska I; Vandenberghe P; De Wolf-Peeters C
    Histopathology; 2005 Apr; 46(4):431-41. PubMed ID: 15810955
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Numeric aberrations of HER-2 and chromosome 17 detected by fluorescence in situ hybridization in urine-exfoliated cells from patients with urothelial carcinoma.
    Inoue T; Sato K; Tsuchiya N; Matsuura S; Iinuma M; Habuchi T; Kato T
    Urology; 2004 Sep; 64(3):617-21. PubMed ID: 15351620
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
    Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A
    Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer.
    Kerns BJ; Jordan PA; Huper G; Marks JR; Iglehart JD; Layfied LJ
    Mod Pathol; 1993 Nov; 6(6):673-8. PubMed ID: 7905629
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detection of Her-2/neu oncogene in breast carcinoma by chromogenic in situ hybridization in cytologic specimens.
    Lin F; Shen T; Prichard JW
    Diagn Cytopathol; 2005 Dec; 33(6):376-80. PubMed ID: 16299744
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Potential for molecular targeted therapy of HER-2/neu for invasive bladder cancer: examination of gene amplification by fluorescence in situ hybridization.
    Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Hirano M; Hayashida K; Mizumukai E; Nanaura H; Honda N
    Oncol Rep; 2007 Nov; 18(5):1183-7. PubMed ID: 17914570
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Amplification and overexpression of HER-2/neu are uncommon in advanced stage melanoma.
    Persons DL; Arber DA; Sosman JA; Borelli KA; Slovak ML
    Anticancer Res; 2000; 20(3B):1965-8. PubMed ID: 10928135
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinicopathological relevance of HER2/neu and a related gene-protein cubic regression correlation in colorectal adenocarcinomas in Taiwan.
    Li JW; Chuang TC; Yang AH; Hsu CK; Kao MC
    Int J Oncol; 2005 Apr; 26(4):933-43. PubMed ID: 15753987
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization.
    Ishikawa T; Kobayashi M; Mai M; Suzuki T; Ooi A
    Am J Pathol; 1997 Sep; 151(3):761-8. PubMed ID: 9284825
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome.
    Peiró G; Mayr D; Hillemanns P; Löhrs U; Diebold J
    Mod Pathol; 2004 Mar; 17(3):227-87. PubMed ID: 14752523
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HER-2/neu amplification and overexpression in endometrial carcinoma.
    Rolitsky CD; Theil KS; McGaughy VR; Copeland LJ; Niemann TH
    Int J Gynecol Pathol; 1999 Apr; 18(2):138-43. PubMed ID: 10202671
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness.
    Goebel SU; Iwamoto M; Raffeld M; Gibril F; Hou W; Serrano J; Jensen RT
    Cancer Res; 2002 Jul; 62(13):3702-10. PubMed ID: 12097278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.